The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Global trends in phase I trials: Changes in cancer types of enrolled patients in 1991-2015.
 
Kota Itahashi
No Relationships to Disclose
 
Toshio Shimizu
Honoraria - Boehringer Ingelheim; Ono Pharmaceutical; Ono Pharmaceutical
Speakers' Bureau - Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; PharmaMar
 
Takafumi Koyama
No Relationships to Disclose
 
Shunsuke Kondo
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
 
Yutaka Fujiwara
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)